王 晶,毛李征,甘軼文,俞海國
·臨床研究·
肺炎支原體肺炎患兒血清白介素17和白介素23水平變化及其臨床意義
王 晶,毛李征,甘軼文,俞海國
目的 觀察肺炎支原體肺炎患兒血清白介素17(IL-17)和白介素23(IL-23)水平變化,并探討其臨床意義。方法 選取2013—2014年東南大學(xué)醫(yī)學(xué)院附屬南京同仁醫(yī)院收治的肺炎支原體肺炎患兒40例作為觀察組,同時(shí)選取健康兒童40例作為對(duì)照組。觀察組患兒入院后進(jìn)行常規(guī)治療,比較兩組兒童治療前后血清IL-17和IL-23水平及C反應(yīng)蛋白異常率。結(jié)果 觀察組患兒治療前血清IL-17和IL-23水平均高于對(duì)照組(P<0.05);兩組兒童治療后血清IL-17和IL-23水平比較,差異無統(tǒng)計(jì)學(xué)意義(P>0.05),且觀察組患兒治療后血清IL-17和IL-23水平均低于治療前(P<0.05)。觀察組患兒治療前C反應(yīng)蛋白異常率高于對(duì)照組(P<0.05);兩組兒童治療后C反應(yīng)蛋白異常率比較,差異無統(tǒng)計(jì)學(xué)意義(P>0.05)。結(jié)論 檢測(cè)血清IL-17和IL-23 水平對(duì)了解肺炎支原體肺炎患兒疾病進(jìn)展及療效有一定臨床意義,可作為其病情發(fā)展、轉(zhuǎn)歸的評(píng)價(jià)指標(biāo)。
肺炎,支原體;白細(xì)胞介素17;白細(xì)胞介素23
肺炎支原體肺炎是指由肺炎支原體引起的肺炎,是兒童最為常見的感染性疾病[1]。近年來,兒童肺炎支原體肺炎發(fā)病率逐年增高,其不僅可對(duì)肺部造成損害,還可引起多臟器損傷,嚴(yán)重時(shí)可導(dǎo)致患兒死亡,極大地威脅著兒童的生命安全[2]。研究表明,肺炎支原體肺炎患兒血清白介素17(IL-17)和白介素23(IL-23)水平會(huì)出現(xiàn)明顯變化,并在肺炎支原體肺炎的發(fā)生、發(fā)展過程中發(fā)揮著重要作用[3]。本研究旨在觀察肺炎支原體肺炎患兒血清IL-17和IL-23水平變化,并探討其臨床意義,現(xiàn)報(bào)道如下。
1.1 一般資料 選取2013—2014年東南大學(xué)醫(yī)學(xué)院附屬南京同仁醫(yī)院收治的肺炎支原體患兒40例作為觀察組,其中男24例,女26例;年齡1~10歲,平均年齡(4.1±2.0)歲;均符合第7版《實(shí)用兒科學(xué)》中肺炎支原體肺炎診斷標(biāo)準(zhǔn):起病緩慢,有呼吸道感染癥狀和體征,如發(fā)熱、陣發(fā)性刺激性咳嗽等,X線檢查示肺部有浸潤性陰影或間質(zhì)性改變。同時(shí)選取健康兒童40例作為對(duì)照組,其中男23例,女27例;年齡1~9歲,平均年齡(4.1±2.1)歲。兩組兒童的性別、年齡間具有均衡性。本研究經(jīng)醫(yī)院倫理委員會(huì)審核批準(zhǔn),兒童家長均簽署知情同意書。
1.2 方法 觀察組患兒入院后進(jìn)行常規(guī)治療,比較兩組兒童治療前后血清IL-17和IL-23水平及C反應(yīng)蛋白異常率。采用酶聯(lián)免疫吸附試驗(yàn)(ELISA)檢測(cè)血清IL-17和IL-23水平,采用免疫比濁法測(cè)定血清C反應(yīng)蛋白水平。
2.1 兩組兒童治療前后血清中IL-17和IL-23水平比較 觀察組患兒治療前血清IL-17和IL-23水平均高于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(P<0.05);兩組兒童治療后血清IL-17和IL-23水平比較,差異無統(tǒng)計(jì)學(xué)意義(P>0.05),觀察組患兒治療后血清IL-17和IL-23水平均低于治療前,差異有統(tǒng)計(jì)學(xué)意義(P<0.05,見表1)。
Table 1 Comparison of serum levels of IL-17 and IL-23 between the two groups before and after treatment
組別例數(shù)IL?17治療前 治療后IL?23治療前 治療后對(duì)照組40137 78±16 04138 43±15 76139 22±15 09139 74±15 13觀察組40170 51±20 75140 22±16 75a344 94±20 27139 25±18 68at值12 6520 5439 6490 879P值<0 0010 898<0 0010 645
注:與治療前比較,aP<0.05;IL-17=白介素17,IL-23=白介素23
2.2 兩組兒童治療前后C反應(yīng)蛋白異常率比較 觀察組患兒治療前C反應(yīng)蛋白異常率高于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(P<0.05);兩組兒童治療后C反應(yīng)蛋白異常率比較,差異無統(tǒng)計(jì)學(xué)意義(P>0.05,見表2)。
肺炎支原體是能在無細(xì)胞培養(yǎng)基上生長的最小微生物之一,直徑125~150 μm,無細(xì)胞壁結(jié)構(gòu),能在含有血清和甾醇的瓊脂培養(yǎng)基上生長,2~3周后其菌落呈煎蛋狀,當(dāng)中較厚,周圍低平[4]。支原體可經(jīng)口、鼻分泌物在空氣中傳播,會(huì)引起散發(fā)呼吸道感染或者小流行。肺炎支原體肺炎占非細(xì)菌性肺炎的1/3以上,占各種原因引起的肺炎的10%,常于秋季發(fā)病,患者以兒童和青年人居多[5];該病起病緩慢,潛伏期為2~3周,病初常有全身不適、乏力、頭痛等;2~3 d后可出現(xiàn)發(fā)熱(體溫常達(dá)39 ℃),可持續(xù)1~3周,可伴有咽痛和肌肉酸痛;咳嗽為本病突出的癥狀,一般于發(fā)病后2~3 d開始出現(xiàn),初為干咳,后轉(zhuǎn)為頑固性劇咳、常伴有有黏稠痰液或偶帶血絲,少數(shù)患者可出現(xiàn)類似百日咳樣陣咳,可持續(xù)1~4周,肺部體征多不明顯,甚至全無,少數(shù)患者可聞及干、濕啰音,但很快消失,故患者體征與劇咳、發(fā)熱等臨床癥狀不一致為本病特點(diǎn)之一。嬰幼兒肺炎支原體肺炎起病急、病程長、病情較重,患兒主要表現(xiàn)為呼吸困難、喘憋、喘鳴音增強(qiáng),肺部啰音較多,部分患兒可出現(xiàn)溶血性貧血、腦膜炎、心肌炎、呻吟、格林-巴利綜合征等肺外表現(xiàn),診斷時(shí)需綜合臨床癥狀、胸部X線表現(xiàn)及血清學(xué)檢查結(jié)果等,痰培養(yǎng)分離出肺炎支原體對(duì)診斷肺炎支原體肺炎有決定性意義,但其檢出率較低、技術(shù)條件要求高、所需時(shí)間長[6]。
表2 組兒童治療前后C反應(yīng)蛋白異常率比較〔n(%)〕
Table 2 Comparison of the abnormal rate of C-reactive protein between the two groups before and after treatment
組別例數(shù)治療前治療后對(duì)照組402(5 0)1(2 5)觀察組4027(67 5)3(7 5)χ2值13 9490 785P值<0 0010 885
本研究結(jié)果顯示,觀察組患兒治療前血清IL-17和IL-23水平均高于對(duì)照組,兩組兒童治療后血清IL-17和IL-23水平間無差異,且觀察組患兒治療后血清IL-17和IL-23水平均低于治療前,說明血清IL-17和IL-23水平可以作為反映肺炎支原體肺炎患兒炎癥程度與疾病進(jìn)展的指標(biāo),這與Hirao等[7]研究結(jié)果一致。觀察組患兒治療前C反應(yīng)蛋白異常率高于對(duì)照組,而兩組兒童治療后C反應(yīng)蛋白異常率間無差異;C反應(yīng)蛋白為炎癥反映指標(biāo),經(jīng)治療炎癥程度降低后會(huì)出現(xiàn)明顯好轉(zhuǎn),血清IL-17和IL-23水平變化趨勢(shì)與之相一致,本研究結(jié)果與呂響紅等[8]研究結(jié)果一致。
綜上所述,檢測(cè)血清IL-17和IL-23 水平對(duì)了解肺炎支原體肺炎患兒疾病進(jìn)展和療效有一定臨床意義,可作為其病情發(fā)展、轉(zhuǎn)歸的評(píng)價(jià)指標(biāo)。
[1]李玉紅.Clara細(xì)胞分泌蛋白、IL-17在支原體肺炎患兒血清中的表達(dá)和意義[D].濟(jì)南:山東大學(xué),2014.
[2]陸敏,付漢東,張愛華,等.肺炎支原體感染患兒血清IL-17、IL-23表達(dá)及臨床意義[J].中華全科醫(yī)學(xué),2012,10(3):374-376.
[3]呂彩霞,陳敬國,陸俊秀.肺炎支原體肺炎喘息患兒血清IL-5的變化及意義[J].中國婦幼衛(wèi)生雜志,2013,30(2):34-35.[4]呂彩霞,陳敬國,陸俊秀.肺炎支原體肺炎喘息患兒血清IL-12的變化及意義[J].航空航天醫(yī)學(xué)雜志,2013,24(6):697-698.
[5]王冬梅,姜采榮,王茹,等.肺炎支原體肺炎患兒血清白介素-23/白介素-17的表達(dá)[J].臨床兒科雜志,2013,31(10):933-936.
[6]王鑫,馬春艷,張亞京,等.肺炎支原體肺炎患兒外周血Th1/Th2表達(dá)及肺功能變化的臨床意義[J].中華臨床醫(yī)師雜志:電子版,2014,8(6):1031-1035.
[7]Hirao S,Wada H,Nakagaki K,et al.Inflammation provoked by Mycoplasma pneumoniae extract:implications for combination treatment with clarithromycin and dexamethasone[J].FEMS Immunol Med Microbiol,2011,62(2):182-189.
[8]呂響紅,吳蒙蒙,張秋業(yè).肺炎支原體肺炎患兒血清IL-27水平變化及其意義[J].中國臨床研究,2014,29(9):1124-1126.
(本文編輯:崔沙沙)
Changes and Clinical Significances of Serum Levels of Interleukin-17 and Interleukin-23 in Children with Mycoplasma Pneumoniae Pneumonia
WANGJing,MAOLi-zheng,GANYi-wen,etal.NanjingTongrenHospitalAffiliatedtoMedicalCollegeofSoutheastUniversity,Nanjing211100,China
Objective To observe the changes of serum levels of interleukin-17(IL-17)and interleukin-23(IL-23)in children with mycoplasma pneumoniae pneumonia,to explore their clinical significances.Methods A total of 40 children with mycoplasma pneumoniae pneumonia were selected as observation group from 2013 to 2014 in Nanjing Tongren Hospital Affiliated to Medical College of Southeast University,and 40 healthy children were selected as control group at the same time.Children of observation group were given conventional treatment after treatment.Serum levels of IL-17 and IL-23,abnormal rate of C-reactive protein were compared between the two groups before and after treatment.Results Before treatment,serum levels of IL-17 and IL-23 of observation group were statistically significantly higher than those of control group(P<0.05);after treatment,no statistically significant differences of serum level of IL-17 or IL-23 was found between the two groups(P>0.05),while serum levels of IL-17 and IL-23 of observation group were statistically significantly lower than those before treatment(P<0.05).Before treatment,the abnormal rate of C-reactive protein of observation group was statistically significantly higher than that of control group(P<0.05);after treatment,no statistically significant differences of the abnormal rate of C-reactive protein was found between the two groups(P>0.05).Conclusion Detection of serum levels of IL-17 and IL-23 is with certain clinical significance to judge the disease progression and efficacy in children with mycoplasma pneumoniae pneumonia,can be used as evaluation index for disease development and clinical outcome.
Pneumonia,mycoplasma;Interleukin-17;Interleukin-23
211100江蘇省南京市,東南大學(xué)醫(yī)學(xué)院附屬南京同仁醫(yī)院(王晶,毛李征,甘軼文);南京市兒童醫(yī)院(俞海國)
王晶,毛李征,甘軼文,等.肺炎支原體肺炎患兒血清白介素17和白介素23水平變化及其臨床意義[J].實(shí)用心腦肺血管病雜志,2015,23(6):156-157,160.[www.syxnf.net]
R 563.13
B
10.3969/j.issn.1008-5971.2015.06.054
2015-03-13;
2015-06-05)
Wang J,Mao LZ,Gan YW,et al.Changes and clinical significances of serum levels of interleukin-17 and interleukin-23 in children with mycoplasma pneumoniae pneumonia[J].Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease,2015,23(6):156-157,160.